Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(10):1382–1386. doi: 10.1038/bjc.1997.564

Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

A M Gillespie 1, P C Lorigan 1, C R Radstone 1, J C Waterhouse 1, R E Coleman 1, B W Hancock 1
PMCID: PMC2228140  PMID: 9374387

Abstract

The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7 with folinic acid 7.5 mg orally 24 h after each methotrexate injection. There is a 7-day rest between treatment cycles. Remission is achieved in 85% of cases. Approximately 20% of patients experienced pleuritic chest pain and dyspnoea. We have evaluated prospectively lung function in 16 low-risk patients receiving methotrexate. All patients had pulmonary function tests [spirometry-forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and transfer factor - TLCO, kCO] performed before and after completed treatment. A mean of 7.5 cycles of MTX were administered (range 4-11). There was a significant reduction in the mean TLCO (mean pre/post 8.15/7.38 mmol min-1 kPa-1, P = 0.01), but there were no other statistically significant changes. Three patients experienced respiratory symptoms and were found to have a 39%, 28%, and 11% reduction in TLCO from baseline, improving on follow up to pretreatment levels. Low-dose MTX is an effective therapy but may cause troublesome pulmonary toxicity.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akoun G. M., Gauthier-Rahman S., Mayaud C. M., Touboul J. L., Denis M. F. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest. 1987 Jan;91(1):96–99. doi: 10.1378/chest.91.1.96. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Whelton J. C., Zizic T. M., Stevens M. B. Methotrexate therapy in polymyositis. Ann Rheum Dis. 1973 Nov;32(6):536–546. doi: 10.1136/ard.32.6.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bagshawe K. D., Dent J., Newlands E. S., Begent R. H., Rustin G. J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989 Jul;96(7):795–802. doi: 10.1111/j.1471-0528.1989.tb03318.x. [DOI] [PubMed] [Google Scholar]
  4. Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  5. Clarysse A. M., Cathey W. J., Cartwright G. E., Wintrobe M. M. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA. 1969 Sep 22;209(12):1861–1868. [PubMed] [Google Scholar]
  6. Huffman D. H., Wan S. H., Azarnoff D. L., Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):572–579. doi: 10.1002/cpt1973144part1572. [DOI] [PubMed] [Google Scholar]
  7. Lurain J. R., Brewer J. I., Torok E. E., Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol. 1983 Mar 1;145(5):591–595. doi: 10.1016/0002-9378(83)91202-4. [DOI] [PubMed] [Google Scholar]
  8. Nesbit M., Krivit W., Heyn R., Sharp H. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer. 1976 Feb;37(2 Suppl):1048–1057. doi: 10.1002/1097-0142(197602)37:2+<1048::aid-cncr2820370811>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  9. Rustin G. J., Newlands E. S., Lutz J. M., Holden L., Bagshawe K. D., Hiscox J. G., Foskett M., Fuller S., Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996 Oct;14(10):2769–2773. doi: 10.1200/JCO.1996.14.10.2769. [DOI] [PubMed] [Google Scholar]
  10. Rustin G. J., Pektasides D., Bagshawe K. D., Newlands E. S., Begent R. H. Fertility after chemotherapy for male and female germ cell tumours. Int J Androl. 1987 Feb;10(1):389–392. doi: 10.1111/j.1365-2605.1987.tb00208.x. [DOI] [PubMed] [Google Scholar]
  11. Sostman H. D., Matthay R. A., Putman C. E., Smith G. J. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976 Sep;55(5):371–388. doi: 10.1097/00005792-197609000-00002. [DOI] [PubMed] [Google Scholar]
  12. White D. A., Rankin J. A., Stover D. E., Gellene R. A., Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989 Jan;139(1):18–21. doi: 10.1164/ajrccm/139.1.18. [DOI] [PubMed] [Google Scholar]
  13. Willson J. K. Pulmonary toxicity of antineoplastic drugs. Cancer Treat Rep. 1978 Dec;62(12):2003–2008. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES